New publication - Attana’s technology was applied in the development of antibody fragments, which potentially could be used in future cancer tumor targeting.

In a new paper published in Nature Communications by the group of Prof. Maurice at University Medical Center Utrecht, single chain antibody fragments that block cellular signaling and thus potentially can be used for future tumor targeting were developed. Attana’s technology was used to select the most promising candidates.

The development of some cancer types is associated with increased expression of Wnt receptors. Therapeutic targeting of these receptors is thus a promising treatment. In this paper, antibody fragments, so called single-domain antibodies (VHHs) targeting the Wnt receptors LRP5/6 were developed. Three highly potent VHHs that interact with the receptors and inhibit cellular responses were identified. With the help of Attana’s technology, the kinetic interaction profile of the VHHs were characterized. The VHHs were shown to target a specific type of tumors, which are sensitive to Wnt. Targeting cancer cells with these VHHs is therefore a potentially promising strategy for treatment of such tumors.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit or contact